RE:RE:RE:RE:RE:RE:RE:Merck KGaA/Pfizer's 90 day exclusivity period in effect now
This is an exerept from a conference call.
opportunities for pelareorep and other indications. The 90 day limit to review the confidential interim data provides a finite window that enables a timely decision point. This window will be triggered by the availability of the 16 week data for the last patient recruited in the study.
From what we know onc has enrolled the final patient and that patient should have been in for the 16 weeks by now. What we do not know is what they mean by the availability of the 16 week data so it is not know for sure if the 90 day exclusity period has actually started from what I have been told. I believe that onc was supposed to give a report to pfizer which would then start this timeframe. Whether or not they have to inform shareholders is another question as the company usually keeps as much information as possible close to themselves.
I have sent an email to onc asking for a clarification on all the points and if whether they can say that this 90 days has actually started.